Analytical Data
-
Gene name
bp26
- Application
-
Alternative Names
(28 kDa cytosoluble protein)(28 kDa outer membrane protein)(CP28)
-
Species
Brucella melitensis biotype 1
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0A3U8
-
Expression Region
29-250aa
-
Molecular Weight
31.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The BP26 recombinant protein, derived from the pathogen responsible for several diseases in animals, particularly in the genus *Brucella*, has garnered significant interest in the fields of veterinary medicine and immunology. This protein is known for its potential role in eliciting immune responses and has been explored for its utility in vaccine development and diagnostic assays. Research into BP26 focuses on understanding its structure, function, and immunogenic properties, as it could serve as a crucial target for the design of vaccines aimed at controlling brucellosis, which poses serious zoonotic threats. Additionally, owing to its immunogenic nature, BP26 is being evaluated as a biomarker for detecting *Brucella* infections in livestock, thereby contributing to better disease management strategies. The ongoing studies on BP26 recombinant protein are pivotal in enhancing our knowledge of the immune mechanisms involved in brucellosis, ultimately aiming to improve health outcomes for both animals and humans affected by this significant pathogen.
